Novartis Faces Patent Expirations but Sees Growth in New Medicines
Novartis reported a challenging first-quarter performance due to patent expirations, with revenue declining slightly and core earnings falling. However, the company's newer medicines showed strong growth potential across several key products.
Topics: blockbuster drugs earnings growth portfolio patent cliff R&D investment